WHO's Solidarity trial in a new phase will test three potential COVID-19 medications techydeed.com

The study started in June 2021 and will continue until May 2022. It is currently being done in more than 600 hospitals across 52 countries.

The second phase of the World Health Organization’s (WHO) Solidarity PLUS trial is now underway. It will be testing four new therapies – Artesunate, imatinib and infliximab – to treat COVID-19.

There were four drugs: remdesivir (hydroxychloroquine), lopinavir, interferon, and hydroxychloroquine. Evaluation of a previous Solidarity PLUS trial They found that they had little or no effect upon hospitalized patients void-19

An independent panel of experts selected these drugs because they could lower the death risk for patients in hospitals.COVID-19 These are the manufacturers of these. These are the manufactures Donations of medicines that were made. Thank you for participating in the trials.

Also Read: Quest and LabCorp offer COVID-19 Antibody Testing. But should you get one?

The World Health Organization’s Solidarity PLUS trial is the world’s largest ongoing randomized control trial of potential COVID-19 therapeutics. It is the largest international collaboration between the WHO Member States.

It allows the trial to simultaneously evaluate multiple treatments using the same protocols, thanks to the involvement of thousands of patients and researchers. They can also get solid estimates of the drug’s impact on mortality, even moderate ones.

The WHO adds new treatments to its guidelines while dropping ineffective, unsafe, or ineffective.

The study started in June 2021 and will continue until May 2022. The study is currently being carried out in more than 600 hospitals across 52 countries.

“Finding more effective and accessible therapeutics for COVID-19 patients remains a critical need, and WHO is proud to lead this global effort,” said Dr. Tedros Adhanom Ghebreyesus, WHO Director-General.

These drugs include:

Also Read: Additional COVID vaccine approved by the US. for people with weak immunity

  • Ipca manufactures Artesunate It to treat malaria. It is made from the herb Artemisia Annua. Artemisinin is a derivative that Artesunate has been used for malaria treatment for more than 30 years. Artesunate can be considered very safe. Artemisia, also known as Sweet Wormwood, can be found in Asia and North America. The standard malaria treatment will be administered intravenously for seven consecutive days. Its anti-inflammatory properties and effectiveness will also be evaluated.
  • Imatinib Novartis produces it, and it is used as a cancer treatment. It’s an oral drug. Early experimental data suggest that it may “reverse the pulmonary capillary loss.” It is administered orally for 14 days daily.
  • Infliximab Johnson and Johnson have produced it and uses it to treat immune-system-related diseases. It is a TNFalpha inhibitor. This chimeric monoclonal antibody recognizes human TNFalpha. These anti-TNF medications have been used for over 20 years. They have been proven safe and effective in reducing inflammation across a broad spectrum, even in the elderly population who are clinically most vulnerable.COVID-19. The standard does Crohn’s Disease patients received intravenously will be administered.

LEAVE A REPLY

Please enter your comment!
Please enter your name here